Success Metrics

Clinical Success Rate
88.9%

Based on 16 completed trials

Completion Rate
89%(16/18)
Active Trials
1(5%)
Results Posted
75%(12 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_1
4
18%
Ph not_applicable
3
14%
Ph phase_4
2
9%
Ph early_phase_1
2
9%
Ph phase_2
11
50%

Phase Distribution

6

Early Stage

11

Mid Stage

2

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
2(9.1%)
Phase 1Safety & dosage
4(18.2%)
Phase 2Efficacy & side effects
11(50.0%)
Phase 4Post-market surveillance
2(9.1%)
N/ANon-phased studies
3(13.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.2%

16 of 19 finished

Non-Completion Rate

15.8%

3 ended early

Currently Active

1

trials recruiting

Total Trials

22

all time

Status Distribution
Active(1)
Completed(16)
Terminated(3)
Other(2)

Detailed Status

Completed16
Terminated2
unknown2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
1
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (9.1%)
Phase 14 (18.2%)
Phase 211 (50.0%)
Phase 42 (9.1%)
N/A3 (13.6%)

Trials by Status

withdrawn15%
terminated29%
recruiting15%
unknown29%
completed1673%

Recent Activity

1 active trials
Showing 5 of 22
completedphase_2

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

NCT05624528
completedphase_2

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498
completedearly_phase_1

Remediation of Impaired Self-Regulation in Patients With Mild TBI

NCT02260570
completedphase_2

Effects of Tolcapone on Frontotemporal Dementia

NCT00604591
terminatedphase_1

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

NCT02630043
View all 22 trials

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT05624528Phase 2

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Completed
NCT03904498Phase 2

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

Completed
NCT02260570Early Phase 1

Remediation of Impaired Self-Regulation in Patients With Mild TBI

Completed
NCT00604591Phase 2

Effects of Tolcapone on Frontotemporal Dementia

Completed
NCT02630043Phase 1

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

Terminated
NCT06387771Phase 2

Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia

Recruiting
NCT02949934Phase 2

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Completed
NCT00927563Phase 2

Tolcapone Treatment of Pathological Gambling

Completed
NCT02929485Phase 4

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

Withdrawn
NCT02772978Not Applicable

Dopamine Responsivity in Gamblers

Completed
NCT02448654Not Applicable

Treatment for Nicotine Addiction in Women

Completed
NCT01158950Not Applicable

A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors

Completed
NCT02740582Phase 2

Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

Completed
NCT03591757Early Phase 1

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Completed
NCT03633591Phase 1

A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

Completed
NCT00044083Phase 2

Clinical Trial of Tolcapone for Cognition in Schizophrenia

Terminated
NCT01202955Phase 2

Pilot Study of Tolcapone in Smokers

Completed
NCT02652598Phase 2

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

Unknown
NCT00033059Phase 1

Assessment of Potential Interactions Between Cocaine and Tolcapone - 1

Unknown
NCT02080715Phase 1

Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22